Dual-isocenter MR-Linac workflow treats 24-cm prostate and pelvic targets in one patient
A dual-isocenter MR-Linac workflow treated a 24-cm continuous prostate and pelvic target, achieving high gamma passing rates in its first clinical application.
A dual-isocenter MR-Linac workflow treated a 24-cm continuous prostate and pelvic target, achieving high gamma passing rates in its first clinical application.
In 378 prostate cancer patients, ten-year biochemical control was 79.6% with one HDR boost fraction versus 82.6% with two, while severe urinary toxicity differed.
After five years, biochemical control was 80.5% with single-fraction 24 Gy versus 85.1% with five-fraction 45 Gy, without proven equivalence.
In oligometastatic hormone-sensitive prostate cancer, comprehensive SBRT plus intermittent ADT produced 78.2% five-year survival and 15.2% failure-free survival.
A new framework combines MRI and radiotherapy device risks into six operational classes for prostate SBRT on a 1.5-T MR-linac.
PREDICT achieved AUC 0.793 versus 0.749 for Roach in SEER, but its apparent advantage did not persist across external cohorts.
In SRAM, weekly pelvic SBRT produced similar grade ≥2 toxicity but worse bowel quality-of-life scores at 9 and 12 months versus IMRT.
In 20 high-risk prostate cancer patients, MRI and PSMA-PET boost targets frequently disagreed, with significantly lower dose coverage of PET-defined lesions.
In 20 prostate patients with hip replacements, implant-trained synthetic CT models closely reproduced CT dose, but two cases with rectal air had outliers.
In TARGET, focal VMAT or HDR brachytherapy boosts achieved 98.5% three-year control within treated prostate lesions, while four recurrences arose outside the boost.
Across 401 non-spinal prostate cancer bone metastases, SBRT achieved 93.3% three-year local control, with higher dose and SIB associated with better progression-free survival.
Across 250 prostate SBRT fractions, adaptive planning prevented major target undercoverage, while most scheduled plans remained close to the prescription dose.
Only 42.1% of prostate RT patients completed their first five fractions without preparation-related corrections, although individual-fraction success increased from 72.9% to 86.6%.
In 378 prostate SABR patients, rectal spacer use was associated with lower one-year grade ≥1 gastrointestinal toxicity after adjustment (OR 0.31).
Updated ASTRO guidance favors moderate hypofractionation for all risk groups, supports five-fraction SBRT in selected patients, and restricts ultrahypofractionated pelvic nodal RT to trials.